Scott Kopetz, MD, PhD, FACP
Encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) demonstrated a significant improvement in overall survival (OS) compared with cetuximab and an irinotecan-containing regimen in patients with BRAF
-mutant colorectal cancer (CRC), according to results of the phase III BEACON CRC study that were presented at the 2019 World Congress on Gastrointestinal Cancers.1
In the study, the triplet regimen elicited a median OS of 9.0 months compared with 5.4 months in the standard-of-care arm, leading to a 48% reduction in the risk of death (HR, 0.52; 95% CI, 0.39-0.70; 2 sided P
<.0001). Moreover, the overall response rates (ORRs) were 26% and 2% for encorafenib/binimetinib/cetuximab and standard therapy, respectively.
"This study builds on a decade of research into the tumor biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumor," Scott Kopetz, MD, lead BEACON CRC study author, stated in a press release ahead of the meeting. "We are encouraged to see a meaningful improvement in outcomes with this new regimen for our patients."
... to read the full story